Harvey Morgan Net Worth

The estimated Net Worth of Harvey Morgan is at least $1.21 Million dollars as of 13 August 2018. Mr. Morgan owns over 10,000 units of Artivion Inc stock worth over $684,768 and over the last 17 years he sold CRY stock worth over $325,400. In addition, he makes $195,015 as Independent Director at Artivion Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Morgan CRY stock SEC Form 4 insiders trading

Harvey has made over 1 trades of the Artivion Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of CRY stock worth $325,400 on 13 August 2018.

The largest trade he's ever made was selling 10,000 units of Artivion Inc stock on 13 August 2018 worth over $325,400. On average, Harvey trades about 357 units every 0 days since 2008. As of 13 August 2018 he still owns at least 38,298 units of Artivion Inc stock.

You can see the complete history of Mr. Morgan stock trades at the bottom of the page.

Harvey Morgan biography

Harvey B. Morgan serves as Independent Director of the Company., He as served as a director of CryoLife since May 2008. Mr. Morgan has more than 40 years of investment banking experience, with significant expertise in strategic advisory services, mergers and acquisitions, private placements, and underwritings. He served as a Managing Director of the investment banking firm Bentley Associates, L.P. from 2004 to December 31, 2012, and from 2001 to 2004 he was a Principal of Shattuck Hammond Partners, an independent investment banking and financial advisory firm. Mr. Morgan also served on the Board of Directors of Family Dollar Stores, Inc. (NYSE: FDO), a leading operator of discount variety stores, from 2007 to 2015, when Family Dollar Stores, Inc. was acquired by Dollar Tree Inc. (NASDAQ: DLTR), and Cybex International, Inc. (NASDAQ: CYBI), a leading manufacturer of premium exercise equipment, from 2003 to 2013. Mr. Morgan received his undergraduate degree from the University of North Carolina at Chapel Hill and an MBA from the Harvard Business School.

What is the salary of Harvey Morgan?

As the Independent Director of Artivion Inc, the total compensation of Harvey Morgan at Artivion Inc is $195,015. There are 10 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of $6,453,540.

How old is Harvey Morgan?

Harvey Morgan is 78, he's been the Independent Director of Artivion Inc since 2008. There are 1 older and 22 younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.

What's Harvey Morgan's mailing address?

Harvey's mailing address filed with the SEC is CRYOLIFE, INC., 1655 ROBERTS BLVD., NW, KENNESAW, GA, 30144.

Insiders trading at Artivion Inc

Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman und James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.

What does Artivion Inc do?

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Complete history of Mr. Morgan stock trades at Artivion Inc

Artivion Inc executives and stock owners

Artivion Inc executives and other stock owners filed with the SEC include:

• James Mackin,
  Chairman of the Board, President, Chief Executive Officer, Director
• D. Ashley Lee,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Jean Holloway,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Michael Simpson,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• John Davis,
  Senior Vice President - Global Sales and Marketing
• James Patrick Mackin,
  Chairman, Pres & CEO
• Scott Capps,
  Vice President - Clinical Research
• David Ashley Lee CPA, CPA,
  Exec. VP, COO & CFO
• Jean F. Holloway Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• John E. Davis,
  Sr. VP of Global Sales & Marketing
• Harvey Morgan,
  Independent Director
• Daniel Bevevino,
  Independent Director
• Ronald McCall,
  Presiding Independent Director
• Thomas Ackerman,
  Independent Director
• Jon Salveson,
  Independent Director
• James Bullock,
  Independent Director
• Jeffrey Burbank,
  Independent Director
• Marna Borgstrom,
  Independent Director
• Greg Chodaczek,
  IR Contact Officer
• Matthew Getz,
  Vice President - Human Resources
• Dennis Maier,
  Vice President - Operations
• Amy Horton,
  Chief Accounting Officer, Vice President
• Thomas Bogenschutz,
  Senior Vice President - EMEA, General Manager - Hechingen
• Dr. Marshall S. Stanton,
  Sr. VP of Clinical Research & Chief Medical Officer
• Joshua Wells,
  Sr. Director of Bus. Devel.
• Matthew A. Getz,
  VP of HR
• Amy D. Horton CPA, CPA,
  VP & Chief Accounting Officer
• Sherry M Saurini,
  VP, Quality
• C Elkins Ronald,
  Director
• James Benson,
  Director
• James M Mc Dermid,
  SVP, CHRO
• David C Gale,
  VP-Research and Development
• William Robert Matthews,
  Senior VP, Operations, Quality
• Thomas J Bogenschuetz,
  VP, EMEA & General Manager
• Bruce G. Anderson,
  VP, US Sales and Marketing
• Jeffrey W Burris,
  Vice President & Gen. Counsel
• Gerald B Seery,
  Sr. VP, Sales and Marketing
• John M Cook,
  Director
• David P. Lang,
  Sr. VP, Intl Sales & Marketing
• Steven G Anderson,
  President, CEO and Chairman
• Thomas J Lynch,
  VP - Reg. Aff./Quality Assur.
• Capital Management Oss,
  10% owner
• Philip A Theodore,
  VP, General Counsel
• Michaelstark Brian Jay Roth,
  
• Sidney B Ashmore,
  Vice President of Marketing
• Virginia C Lacy,
  Director
• Dyne Bruce J Md Van,
  Director
• Albert E Heacox,
  Sr. VP-Laboratory Operations
• Vander James C Wyk,
  VP - Product Integrity
• Kirby S Black,
  Sr. Vice President, R&D
• David Fronk,
  VP - Clinical Research
• Rochelle L. Maney,
  VP, Quality
• Franz Peter Barthold,
  VP, Research & Development
• Marshall S. Stanton,
  SVP, Clinical & MD Affair
• Anthony B. Semedo,
  Director